Evidence map›Paper›PMID 41942468›Full record

ArticleCell death & disease2026

The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.

J Searle, M Menotti, W J McDaid, M J Baker, A Chaturvedi, L Ginn, H Reed, M Carter, F Blackhall, C R Lindsay and 1 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

J SearleCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. Joshua.searle@ucl.ac.uk.ORCID http://orcid.org/0000-0002-1055-0247
M MenottiCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
W J McDaidCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
M J BakerCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
A ChaturvediCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
L GinnCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
H ReedCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
M CarterCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
F BlackhallCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
C R Lindsay *Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
A Malliri *Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. angeliki.malliri@manchester.ac.uk.

Funding

Cancer Research UK (CRUK) A20465Cancer Research UK (CRUK) A25146Cancer Research UK (CRUK) A25254Cancer Research UK (CRUK) A27412
6 · The paper itself

Abstract

The E3 ubiquitin ligase HUWE1 modifies a diverse network of substrate proteins by ubiquitination, through which it regulates various intracellular processes and contributes to both oncogenic and tumour suppressor mechanisms in different cancer contexts. Here, by analysing human lung adenocarcinoma (LUAD) patient samples, we reveal that HUWE1 protein expression is commonly upregulated in LUAD tumours compared to normal adjacent lung tissue and that this increase is associated with tumour stage. Using multiple, independent murine models of LUAD initiation and growth, we identify that Huwe1 is essential for mutant Kras-induced lung tumour development and reveal a novel, p53-independent requirement for Huwe1 in LUAD. Mechanistically, we demonstrate induction of senescence following HUWE1 depletion - characterised by impaired proliferation, an atypical cell cycle distribution, emergence of morphologically abnormal enlarged cells, increased β-galactosidase activity, and transcriptional reprogramming associated with inflammatory senescence-associated secretory phenotype (SASP) signalling and NFκB activation. Together, these data highlight a crucial role for HUWE1 in mutant Kras-induced LUAD tumorigenesis and in the continued growth and proliferation of established LUAD cells, confirming HUWE1 as a rational therapeutic target for LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Tumor Suppressor ProteinsUbiquitin-Protein LigasesAnimalsCell Line, TumorCell ProliferationCellular SenescenceGene Expression Regulation, NeoplasticHumansMiceSignal TransductionHUWE1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Tumor Suppressor ProteinsUbiquitin-Protein Ligases

Identifiers

PMID41942468
PMCPMC13187489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.